Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lorlatinib + encorafenib + binimetinib + talazoparib + sacituzumab govitecan + axitinib + fam-trastuzumab deruxtecan-nxki + enfortumab vedotin
- Development stage
- Unknown
- Lead developer
- Strata Oncology
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
This is a multi-drug combination regimen consisting of eight targeted anticancer agents: lorlatinib (ALK/ROS1 inhibitor), encorafenib and binimetinib (BRAF and MEK inhibitors), talazoparib (PARP inhibitor), sacituzumab govitecan (Trop-2-directed antibody-drug conjugate with SN-38 topoisomerase I inhibitor payload), axitinib (VEGF receptor inhibitor), fam-trastuzumab deruxtecan-nxki (HER2-directed antibody-drug conjugate with deruxtecan topoisomerase I inhibitor payload), and enfortumab vedotin (Nectin-4-directed antibody-drug conjugate with monomethyl auristatin E payload). It targets multiple oncogenic pathways including ALK fusion, BRAF mutation, DNA repair via PARP, angiogenesis via VEGF, and overexpressed surface antigens (Trop-2, HER2, Nectin-4) in advanced solid tumors. Being evaluated in the StrataPATH precision medicine trial (NCT05097599) for patients with actionable molecular alterations matching these drugs' indications, primarily in non-small cell lung cancer, melanoma, breast cancer, and other solid tumors.[10]
02
Targets
ALK (Anaplastic lymphoma kinase receptor tyrosine kinase)BRAF (B-Raf proto-oncogene, serine/threonine kinase)ERBB2 (Erb-b2 receptor tyrosine kinase 2)MEK1 (Dual specificity mitogen-activated protein kinase kinase 1)MEK2 (Dual specificity mitogen-activated protein kinase kinase 2)PVRL4 (Nectin cell adhesion molecule 4)PARP1 (Poly (adp-ribose) polymerase 1)PARP2 (Poly (adp-ribose) polymerase 2)RAF1 (c-Raf-1 (Y340D/Y341D))ROS1 (Proto-oncogene tyrosine-protein kinase ROS)TACSTD2 (Tumor-associated calcium signal transducer 2)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)
Beyond the preview
Go deeper on lorlatinib + encorafenib + binimetinib + talazoparib + sacituzumab govitecan + axitinib + fam-trastuzumab deruxtecan-nxki + enfortumab vedotin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lorlatinib + encorafenib + binimetinib + talazoparib + sacituzumab govitecan + axitinib + fam-trastuzumab deruxtecan-nxki + enfortumab vedotin.